What is AKR 202 used for?

AKR 202 is indicated for Metastatic triple-negative breast cancer.

AKR 202 is developed by Akron Molecules AG.

What are the side effects of AKR 202?

Common side effects include Fatigue, Nausea, Diarrhea.

Last reviewed 2026-04-23 · How we verify

AKR 202

Akron Molecules AG · Phase 2 active Small molecule

AKR 202 is a small molecule that targets the PI3K/AKT/mTOR pathway.

AKR 202 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic triple-negative breast cancer.

At a glance

Generic name	AKR 202
Sponsor	Akron Molecules AG
Drug class	PI3K/mTOR inhibitor
Target	PI3K/AKT/mTOR pathway
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

AKR 202 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell growth and proliferation. This inhibition can lead to anti-tumor effects. AKR 202 has shown promise in preclinical studies for its ability to selectively target cancer cells.

Approved indications

Metastatic triple-negative breast cancer

Common side effects

Fatigue
Nausea
Diarrhea

Key clinical trials

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AKR 202 CI brief — competitive landscape report
AKR 202 updates RSS · CI watch RSS
Akron Molecules AG portfolio CI